Replies to post #595039 on NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

They can’t even get to regulatory applications for GBM with ph 3 data alone. Forget about tissue agnostic. All deflection tactics used by social media army to avoid questioning around delays with regulatory filings. The narrative has shifted towards ph 2 combo data. No approvals in 2023. And the stock gets slammed again as we head into Q3!